Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) - Mozambique

The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) is supporting efforts in Mozambique to understand the benefits and costs of alternative approaches to preventive chemotherapy (PC) for urinary schistosomiasis (Schistosoma haematobium) in high prevalence (>25%) communities. In total five years of S.haematobium infection data has been collected from 81,167 individuals across 150 communities in Cabo Delgado province, Northern Mozambique, to accurately assess the benefits of different approaches to large scale administration of treatment with Praziquantel (PZQ).

Application: One of the primary objectives is to attain a quantifiable decrease in schistosome prevalence and intensity across a whole age profile as a result of treatment. These results will help identify the most effective treatment strategy in terms of reduction in parasite reduction as well as cost-efficiency.

LCNTDR Research team

External partners

  • Faculdade of Health Sciences, Universidade Católica de Moçambique (UCM) Beira, Moçambique
  • Ministerio da Saude, Maputo, Moçambique